In order to capitalize on the numerous opportunities to commercialize its proprietary Nanopatch™ platform, Vaxxas is pursuing strategic plans to both license its technology to global pharmaceutical companies as well as advance vaccine candidates on its own. Vaxxas has a collaboration with Merck & Co. Inc. to evaluate, develop and commercialize Vaxxas' Nanopatch™ vaccine delivery platform for undisclosed vaccine candidates developed by Merck.
I imagine that OBJ would be very much bound by nondisclosure agreements, plus they are a supplier of technology to Vaxxas, who has a collaboration with Merck. There is no way OBJ will let us know what is happening until there are developments and announcements about further use of the vaccine patches by these companies first.
Hopefully one day we will be knocked off our seats with new info.
(20min delay)